Published on Microbicide Trials Network (http://www.mtnstopshiv.org)

Home > RMP-02/MTN-006

RMP-02/MTN-006

A Phase I safety, acceptability and drug absorption study of tenofovir vaginal gel applied rectally and tenofovir tablets taken orally being conducted in collaboration with the University of California, Los Angeles (UCLA) through the Integrated Preclinical/Clinical Program for HIV Topical Microbicides, National Institute of Allergy and Infectious Diseases.
 
See
Feb 28, 2011
  
Feb 28, 2011
  
     
  
 
See Also
Printer-friendly version [7]
Source URL: http://www.mtnstopshiv.org/news/studies/mtn006

Links:
[1] http://www.mtnstopshiv.org/node/2934
[2] http://www.mtnstopshiv.org/node/2931
[3] http://www.mtnstopshiv.org/news/studies/mtn006/backgrounder
[4] http://www.mtnstopshiv.org/news/studies/mtn006/qa
[5] http://www.mtnstopshiv.org/node/2864
[6] http://www.mtnstopshiv.org/sites/default/files/attachments/P4%20Aim2%20Protocol%20RMP02-MTN%20006%20v1_0_7APRIL09.pdf
[7] http://www.mtnstopshiv.org/print/1598

Media Contacts:

Lisa Rossi -- Office: +1 412 641-8940 -- Mobile: +1 412 916-3315 -- Email: rossil@upmc.edu

Clare Collins -- Office: +1 412 641-7299 -- Mobile: +1 412 770-8643 -- Email: collcx@upmc.edu